{"id":"NCT00128102","sponsor":"Merck Sharp & Dohme LLC","briefTitle":"Suberoylanilide Hydroxamic Acid (Vorinostat, MK-0683) Versus Placebo in Advanced Malignant Pleural Mesothelioma (MK-0683-014)","officialTitle":"A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Oral Suberoylanilide Hydroxamic Acid (Vorinostat, MK-0683) in Patients With Advanced Malignant Pleural Mesothelioma Previously Treated With Systemic Chemotherapy","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2005-06-30","primaryCompletion":"2011-07-15","completion":"2011-11-21","firstPosted":"2005-08-09","resultsPosted":"2020-10-26","lastUpdate":"2020-10-26"},"enrollment":661,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Mesothelioma","Lung Cancer"],"interventions":[{"type":"DRUG","name":"Vorinostat","otherNames":["MK-0683","Zolinza"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Vorinostat","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The goal of this study is to assess the efficacy and safety of an oral investigational drug suberoylanilide hydroxamic acid (vorinostat, MK-0683) compared to placebo, in the treatment of participants with advanced malignant pleural mesothelioma who have failed at least one prior chemotherapy regimen. The primary hypotheses are the following: (1) vorinostat improves overall survival (OS) compared to placebo (2) vorinostat is generally safe and well tolerated.","primaryOutcome":{"measure":"Overall Survival (OS)","timeFrame":"Up to ~72 months (through pre-specified final statistical analysis cut-off date of 15-July-2011)","effectByArm":[{"arm":"Vorinostat","deltaMin":30.7,"sd":null},{"arm":"Placebo","deltaMin":27.1,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.858"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":6},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":["25800891"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":133,"n":329},"commonTop":["Nausea","Fatigue","Decreased appetite","Diarrhoea","Dyspnoea"]}}